Question 1

What counts as a head and neck cancer?

Accepted Answer

Head and neck cancers are tumours of the oral cavity, pharynx (nasopharynx, oropharynx, hypopharynx), larynx, salivary glands, nasal cavity and paranasal sinuses, thyroid, and the skin and lip of the head and neck. They are grouped by anatomy, but their causes, treatments and prognoses differ substantially by subsite.

Question 2

How common is head and neck cancer worldwide?

Accepted Answer

GLOBOCAN 2022 estimates combine to about 947,211 new cases across the six main head and neck cancer subsites, with an age-standardised incidence around 9.8 per 100,000. Lip and oral cavity cancer is the largest group (389,846 cases), followed by laryngeal cancer (189,191).

Question 3

What are the earliest warning signs of head and neck cancer?

Accepted Answer

A painless neck lump, a mouth ulcer or white/red patch lasting more than two to three weeks, persistent hoarseness, one-sided nasal blockage or nosebleeds, difficulty swallowing, unilateral ear pain with a normal ear, and a non-healing lip or facial sore. Persistence beyond two to three weeks — not pain — is the trigger for an ENT examination.

Question 4

How long should I wait before seeing a doctor about a mouth ulcer?

Accepted Answer

No more than two weeks. A traumatic ulcer normally heals within 10–14 days after the cause is removed. Any oral ulcer, red or white patch, lump or loose tooth persisting beyond two to three weeks should be examined and usually biopsied.

Question 5

Can a CT or MRI scan diagnose head and neck cancer?

Accepted Answer

No. Imaging shows the size and extent of an abnormality, but a biopsy read by a head and neck pathologist is required to establish the diagnosis and tumour type before treatment. Biomarker tests (p16/HPV, EBV, PD-L1) are then added on the tissue sample.

Question 6

What is the first test for a persistent neck lump in an adult?

Accepted Answer

Ultrasound-guided fine-needle aspiration (FNA) or core biopsy plus a full head and neck endoscopic examination. An open excisional biopsy as the first step should be avoided because it can seed tumour and complicate later neck dissection and radiotherapy.

Question 7

Is HPV-positive oropharyngeal cancer contagious?

Accepted Answer

The cancer is not contagious. HPV is a common, usually transient infection transmitted between partners, but a diagnosis does not mean a partner is ill or needs cancer screening or treatment. The patient’s tumour HPV status matters because it determines staging and prognosis.

Question 8

Why is oropharyngeal cancer increasing in the US and Northern Europe?

Accepted Answer

Persistent HPV-16 infection now causes about 70% of US oropharyngeal cancers and 52–77% of cases in the UK and Scandinavia. HPV-positive disease is the fastest-growing head and neck cancer in high-income countries, typically in non-smoking men aged 40–60, and has roughly 85% five-year survival.

Question 9

Which head and neck cancer is most common in India and South Asia?

Accepted Answer

Oral cavity cancer, driven by areca nut, betel quid and smokeless tobacco. India recorded 143,759 new cases and 79,979 deaths in 2022; oral cavity cancer makes up 59.8% of the South-Central Asian lip/oral/pharyngeal burden.

Question 10

Which countries have the highest nasopharyngeal cancer rates?

Accepted Answer

The highest age-standardised rates are in South-East Asia: Maldives 7.5 (only 36 cases), Brunei 6.4, Indonesia 6.1, Malaysia 5.9, Singapore 5.4 and Vietnam 4.7 per 100,000. North Africa is a second endemic zone; Algeria’s ASR was 3.5. About 83% of cases occur in Asia.

Question 11

Why is thyroid cancer so common in South Korea?

Accepted Answer

Widespread neck ultrasound detects tiny papillary cancers that would never cause harm — overdiagnosis. South Korea’s ASR (39.5/100,000 in women) is the highest in Asia, yet thyroid cancer mortality remains low (global ASR 0.4). Many small low-risk tumours can be monitored instead of operated on.

Question 12

What is the standard treatment for early-stage head and neck cancer?

Accepted Answer

One modality — surgery or radiotherapy — chosen by subsite and functional considerations. Guideline summaries quote roughly 70–90% five-year survival for stage I–II disease. Locally advanced disease requires combined treatment such as surgery plus postoperative radiotherapy/chemoradiotherapy or definitive cisplatin-based chemoradiotherapy.

Question 13

Why is nasopharyngeal cancer treated with radiotherapy rather than surgery?

Accepted Answer

The nasopharynx lies deep behind the nose next to the skull base and cranial nerves, so wide surgical removal is rarely feasible. The tumour is also highly radiosensitive, making IMRT (typically 33 fractions over 6–7 weeks) the curative standard; surgery is reserved for residual or recurrent disease.

Question 14

Can HPV-positive cancer treatment be reduced because the prognosis is good?

Accepted Answer

Not outside a clinical trial. Randomised studies replacing cisplatin with cetuximab in HPV-positive disease showed worse overall survival, and reduced-dose radiotherapy remains investigational despite the drive to reduce long-term swallowing and salivary toxicity.

Question 15

Will I lose my voice if I have laryngeal cancer?

Accepted Answer

Usually not with early disease. T1–T2 glottic cancers are often cured with radiotherapy or a voice-sparing partial laryngectomy. Total laryngectomy is reserved for advanced or recurrent disease, and speech can still be restored with a tracheoesophageal voice prosthesis, an electrolarynx or oesophageal speech.

Question 16

How often do I need follow-up after head and neck cancer treatment?

Accepted Answer

NCCN survivorship guidance recommends every 1–3 months in year one, every 2–6 months in year two, every 4–8 months in years three to five, and annually thereafter. Visits include a full head and neck examination with endoscopy; TSH is checked every 6–12 months if the neck was irradiated.

Question 17

Why do international patients consider head and neck cancer treatment in China?

Accepted Answer

The usual reasons are short waiting times, high procedural volumes for oral cancer resection and microvascular reconstruction, experience with endemic nasopharyngeal carcinoma, and lower total costs for self-paying patients. A written remote opinion based on your records should always come before travel.

Question 18

How much does head and neck cancer treatment cost in China?

Accepted Answer

Illustrative planning ranges are ¥100,000–¥220,000 (about US$14,000–30,000) for oral cancer resection with free-flap reconstruction and ¥100,000–¥220,000 for a full IMRT course with chemotherapy. Immunotherapy is charged per cycle. These are budgeting figures, not quotations.

Question 19

What medical records should I send before travelling to China for treatment?

Accepted Answer

An English summary, original pathology report and slides or block, contrast CT/MRI/PET-CT on DICOM, p16/HPV and EBV results, full prior-treatment records, recent laboratory tests, dental clearance and current medications. A remote review should precede any booking.

Question 20

How long will I need to stay in China for treatment?

Accepted Answer

A second opinion takes about 3–7 working days; limited surgery 1–3 weeks; major resection with free-flap reconstruction 3–6 weeks; definitive radiotherapy or chemoradiotherapy 7–10 weeks; surgery plus postoperative radiotherapy 10–14 weeks. Book flexible return flights.

Question 21

Can head and neck cancer be prevented?

Accepted Answer

Many cases can: HPV vaccination before exposure, stopping tobacco and areca nut, limiting heavy alcohol, UV protection for the lips and face, dust extraction in wood/nickel/leather work, and early assessment of persistent symptoms. There is no validated population screening test for most head and neck cancers.

Question 22

Which head and neck cancer is most common worldwide?

Accepted Answer

Cancer of the lip and oral cavity: 389,846 new cases in GLOBOCAN 2022 (ASR 4.0/100,000), about 41% of all head and neck cancers. Oral cavity cancer alone (excluding lip) accounted for 317,500 cases in the 2022 subsite analysis.

Question 23

Which head and neck cancer is most common in the United States?

Accepted Answer

Oropharyngeal cancer is the dominant lip/oral/pharyngeal subsite among US men (43.8% of the regional burden), and roughly 70% of US oropharyngeal cancers are HPV-positive. This reflects the HPV-16 epidemic in high-income countries rather than tobacco.

Question 24

Which head and neck cancer is most common in India?

Accepted Answer

Oral cavity cancer. India recorded 143,759 new cases and 79,979 deaths in 2022 — 10.2% of all Indian cancers — with men accounting for about 75%. Chewing tobacco, areca nut and betel quid explain most of the burden.

Question 25

Why is nasopharyngeal cancer so common in South-East Asia but rare in the West?

Accepted Answer

Endemic NPC combines EBV infection with genetic susceptibility and childhood dietary exposure (salt-preserved fish). Nine of the ten highest national ASRs are in South-East Asia; the US ASR is about 0.4/100,000. Asia accounted for 83.3% of the 120,434 global cases in 2022.

Question 26

Is thyroid cancer really increasing, or just being detected more?

Accepted Answer

Mainly being detected more. Incidence has climbed steeply with widespread neck ultrasound — South Korea has the highest reported ASR (39.5/100,000 in women) — while mortality has stayed low (global ASR 0.4). Overdiagnosis of small papillary cancers is the accepted explanation.

Question 27

Why do head and neck cancer rates differ so much between countries?

Accepted Answer

Because the main causes are local exposures: HPV and HPV vaccination coverage, tobacco and areca nut chewing, alcohol, ultraviolet radiation, EBV and dietary patterns, occupational carcinogens, and the intensity of diagnostic imaging. Registry coverage also affects recorded rates.

Question 28

How many head and neck cancers were diagnosed worldwide in 2022?

Accepted Answer

GLOBOCAN 2022 estimates combine to 947,211 cases across lip/oral cavity, salivary glands, oropharynx, nasopharynx, hypopharynx and larynx, with an overall age-standardised incidence of about 9.8 per 100,000. A separate 2026 subsite analysis counted 758,020 lip/oral cavity/pharyngeal cases, excluding the larynx.

Question 29

Should where I live change which symptoms I worry about?

Accepted Answer

Yes, it changes the prior probability. A painless neck lump in North America points strongly toward HPV-positive oropharyngeal cancer; a non-healing cheek ulcer in South Asia toward oral cancer; unilateral nasal obstruction or a blocked ear in South-East Asia or North Africa toward nasopharyngeal carcinoma; and a non-healing lower-lip sore in Australia toward UV-related lip cancer.

Head & Neck Cancer FAQ

Head and neck cancer basics